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and D aorto-iliac lesions were acceptable, with better technical success in TASC C lesions than
in TASC D lesions. Furthermore, the 2-year patency rate for both TASC C and TASC D lesions was
acceptable. Additionally, brachial access was useful for complex anatomy, but the failure rate
was high.
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reserved.1. Introduction
The long-term durability of open bypass is better than that
of endovascular treatment (EVT) for Trans-Atlantic Inter-
Society Consensus (TASC) C and D aorto-iliac lesions.1
However, an operative mortality rate of 2.9% and a
complication rate of 15.3% make open surgery a less
attractive option.
Major changes in the TASC II guidelines in 2007 reflected
the rapid growth of EVT, and many centers have reported
satisfactory results with EVT for TASC C and D aorto-iliac
lesions.2e5 Although the treatment of complex and severe
iliac lesions remains challenging, many recently developed
devices and a variety of access options have increased
success rates.
The aim of this study was to evaluate the technical
success rates, primary patency, and complication for TASC
C and D aorto-iliac lesions treated by endovascular proce-
dure. Additionally, the influence of the access site and the
clinical outcomes were analyzed.
2. Methods
The study was performed in accordance with the Declara-
tion of Helsinki and Good Clinical Practice guidelines. This
study was approved by Seoul St Mary’s Hospital Institutional
Review Board (KCI 13RISI0908) and patient consent was not
needed.
2.1. Patient population
Between 2008 and 2014, data from 39 consecutive patients
with 45 chronic iliac artery stenosis and/or occlusion who
were treated with EVT were retrospectively reviewed. The
TASC II classification of the disease severity for aorto-iliac
lesions was used to define the lesion category. The number
of patients with TASC C and D lesion morphology was 16 (18
limbs) and 23 (29 limbs), respectively. All patients were
judged to be candidates for EVT if they reported disabling
claudication, had failed with medical therapy, or had rest
pain or gangrene (Fontaine stage IIbwIV). Endovascular
first approach in all patients was the treatment of choice
during our study period. Electronic medical records and
angiography images were reviewed for demographic data,
anatomic lesion, procedural factors, complications, and
other outcome variables. Patients with acute limb
ischemia, restenotic lesions, diagnostic arteriography, or no
intention to treat were excluded.n S, et al., Outcomes of endovascu
.1016/j.asjsur.2015.11.0062.2. Treatment procedure
All patients underwent preoperative ankle-brachial indexes
(ABI) and duplex ultrasonography examinations to deter-
mine the need for EVT. Aditionally, all patients had at least
one radiological imaging, including computed tomography
angiography (CTA) or magnetic resonance angiography,
before therapeutic angiography. All patients were given
325 mg of oral aspirin prior to the procedure, 325 mg of
aspirin and 300 mg of clopidogrel immediately post-
operatively, 75mg of clopidogrel for 6 weeks post-
operatively, and 100 mg of aspirin indefinitely.
After placing a 6-Fr introducer sheath into the ipsilateral
and/or contralateral common femoral artery or a 5-Fr
introducer sheath into the left brachial artery, heparin
was administered intravenously at a dose of 5000 IU. After
completing diagnostic angiography, the lesion was crossed
with a guidewire. A 5-Fr straight or slightly curved angiog-
raphy catheter and a 0.035-in hydrophilic guidewire (Gli-
dewire; Terumo, Tokyo) was used to cross the lesion. In
some cases, a hydrophilic guidewire was introduced from
the contralateral side, advanced across the occlusion from
the aortic side of the iliac artery, and grasped with a snare
from the ipsilateral side. If the recanalization attempt
failed via these approaches, antegrade recanalization was
attempted via the brachial approach. The iliac lesion
crossing was achieved in a subintimal or intraluminal
manner depending upon the character of the lesion. The
length and diameter of the lesion were judged by intra-
oprative arteriograms. Predilatation of the occlusion before
stent deployment was performed at the discretion of the
operator. Self-expandable stents for long-segment occlu-
sions or balloon-expandable stents for short-segment oc-
clusions (mostly at the common iliac artery orifice) were
preferred. Selection of the stent type and stent size was
left to the discretion of the operator. Except for early pe-
riods, primary stenting was used in all cases, and the stent
diameter ranged from 7e10 mm. Arterial pressure gradient
was not considered. Patients were generally discharged
within 48 h after the procedure.
2.3. Calcification score
To assess the grade of calcification at the level of the
treated iliac artery lesion, axial CTA images were used.
Circumferential grade was measured by assessing the
presence of calcium in one or more of the four 90 sectors:
score 1 (0e90), score 2 (0e180), score 3 (0e270), and score
4 (0e360).lar treatment for TASC C and D aorto-iliac lesions, Asian Journal of
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Technical success was defined as <30% residual stenosis on
angiography. Procedure-related morbidity and mortality
rates within 30 days were determined.2.5. Follow up
The treated aorto-iliac lesions were assessed by duplex
ultrasonography examination, and ABI was measured at
1 month and 6 months during the first postoperative year
and annually thereafter. CTA was performed when there
were recurrent symptoms, a decrease of 0.15 in ABI,
and/or an increase of >300 cm/s in the peak systolic
velocity.Table 1 Demographic/clinical characteristics.
Total
(nZ39 patients)
Age (mean) 72.9  8.3
Gender (Male) 31 (79.4%)
BMI 22.0  3.3
Smoking 20 (51.2%)
Diabetes mellitus 17 (43.5%)
Hypertension 29 (74.3%)
Dyslipidemia 16 (41%)
Coronary artery disease 7 (17.9%)
Cerebrovascular disease 6 (15.3%)
Renal insufficiency (Cr > 1.2) 5 (12.8%)
COPD 3 (7.6%)
Laboratory findings
Total cholesterol 169  44
LDL cholesterol 100  29
HDL cholesterol 38  10
Triglyceride 155  104
Creatinine 0.97  0.28
ASA score
1 3 (8.1%)
2 25 (67.5%)
3 9 (24.3%)
Limb side
Right 25 (64.1%)
Lleft 20 (51.2%)
Both 6 (15.3%)
Fontaine stage
IIb 22 (56.4%)
III 9 (23.0%)
IV 9 (23.0%)
Post-procedural medications
Aspirin 32 (82.0%)
Clopidogrel 15 (38.4%)
Cilostazol 19 (48.7%)
Wafarin 4 (10.2%)
Berasil 4 (10.2%)
Statin 29 (74.3%)
ASA Z American Society of Anesthesiologists; BMI Z body mass index
HDL Z high-density lipoprotein; LDL Z low-density lipoprotein; ns Z
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Comparisons between patients with TASC C lesions and
TASC D lesions were performed using the Student t test or
Mann-Whitney test for continuous variables and with the
Pearson chi-square or the Fisher exact tests for discrete
variables as appropriate. The Kolmogorov-Smirnov fit test
was performed to ensure normal distribution of the data.
Results are reported as mean  standard deviation for
continuous variables or as counts and percentage of pa-
tients or lesions for categorical data. A p < 0.05 was
considered significant. Comparisons between approaches
were done with the Kruskal-Wallis test for continuous var-
iables and by linear association for discrete variables. Pri-
mary patency of the percutaneous transluminal angioplasty
site was analyzed using the Kaplan-Meier analysis with theTACS C
(nZ16)
TASC D
(nZ23)
p
73.5  7.8 72.4  8.8 0.712
11 (68.7%) 20 (86.9%) 0.235
21.2  3.6 22.8  2.9 0.140
5 (31.2%) 15 (65.2%) 0.037
6 (37.5%) 11 (47.8%) 0.522
11 (68.7%) 18 (78.2%) 0.711
6 (37.5%) 10 (43.4%) 0.709
0 7 (30.4%) 0.029
0 6 (26.0%) 0.064
1 (6.2%) 4 (17.3%) 0.631
1 (6.2%) 2 (8.6%) ns
169  46 168  42 0.961
97  25 103  34 0.580
41  12 35  8 0.171
140  109 170  100 0.441
0.93  0.21 1.01  0.36 0.444
0.377
2 (12.5%) 1 (4.7%)
12 (75%) 13 (61.9%)
2 (12.5%) 7 (33.3%)
10 (62.5%) 15 (65.2%) 0.862
8 (50.0%) 12 (52.1%) 0.894
2 (12.5%) 4 (17.3%) ns
11 (68.7%) 11 (47.8%) 0.195
2 (12.5%) 7 (30.4%) 0.262
4 (25.0%) 5 (21.7%) ns
12 (75.0%) 20 (86.9%) 0.415
5 (31.2%) 10 (43.4%) 0.440
10 (62.5%) 9 (39.1%) 0.151
3 (18.7%) 1 (4.3%) 0.286
1 (6.2%) 3 (13.0%) 0.631
10 (62.5%) 19 (82.6%) 0.264
; COPDZ chronic obstructive pulmonary disease; CrZ creatine;
not significant; TASC Z Trans-Atlantic Inter-Society Consensus.
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18; SPSS Inc, Chicago, IL, USA) was used for all statistical
analyses.
3. Results
3.1. Patients
Baseline demographic and clinical data for the two groups
are shown in Table 1. The baseline characteristics of both
groups were comparable, except for smoking and coronary
artery disease. The more commonly associated comorbidity
in patients with TASC D lesions was coronary artery disease
(30.4%; p Z 0.029).
3.2. Clinical outcome
A total of 47 limbs (39 patients) had been evaluated with
anatomic variables, access site, and time of procedure
(Table 2). Most of the patients were treated forTable 2 Lesion characteristics and summary of results.
Total
(nZ47 limbs)
Indication for treatment
Claudication 26 (57.7%)
Resting pain 9 (20%)
Minor tissue loss 10 (22.2%)
Occlusion 34 (75.5%)
Stump 34 (75.5%)
Aneurysm 1 (2.2%)
Calcification score
1 16 (36.3%)
2 16 (36.3%)
3 10 (22.7%)
4 2 (4.5%)
Infrainguial lesion
A 10 (22.2%)
B 4 (8.8%)
C 4 (8.8%)
D 5 (11.1%)
Initial technical success rates 42 (93.3%)
Procedure time 134  58
Stenting 41 (91.1%)
Diameter (max) 8.5  1.0
Total length 150  56
Number of stent 1.7  1.1
Initial access
Ipsilateral 6 (13.3%)
Counterlateral 15 (33.3%)
Only brachial 9 (20%)
Bifemoral 12 (26.6%)
Brachial & Femoral 3 (6.6%)
Pre ABI 0.49  0.20
Post ABI 0.89  0.18
Complications 5 (11.1%)
Procedure time 134  58
ABI Z ankle-brachial index; ns Z not significant; TASC Z Trans-Atla
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than in TASC C lesions, but statistical significance was not
achieved (61.1% vs. 85.1%, pZ 0.086). Bilateral iliac artery
occlusions were observed in six patients, four of which
were in TASC D lesions. The procedure time was longer for
TASC D lesions than for TASC C lesions (163  82 min vs.
105  34 min; p Z 0.002), where there was more common
use of the brachial and femoral approach simultaneously. A
variety of stents were used in 100% of TASC C lesions and in
85.1% of TASC D lesions (p Z 0.138).
3.3. Complications
There were two perioperative deaths in the TASC D lesion
group, with the causes being one iliac artery rupture and
one postoperative hospital acquired pneumonia. The total
perioperative complication rate was higher in the TASC D
lesion group than in the TASC C lesion group [five (18.5%) vs.
zero; p Z 0.073]. These complications included one distal
embolization, two iliac artery ruptures, one aspiration
pneumonia, and one myocardial infarction. One out of fiveTACS C
(nZ18 limbs)
TASC D
(nZ29 limbs)
p
12 (66.6%) 14 (51.8%) 0.324
2 (11.1%) 7 (25.9%) 0.279
4 (22.2%) 6 (22.2%) ns
11 (61.1%) 23 (85.1%) 0.086
15 (83.3%) 19 (70.3%) 0.482
1 (5.5%) 0 0.400
3 (17.6%) 13 (48.1%) 0.118
9 (52.9%) 7 (25.9%) ns
3 (17.6%) 7 (25.9%) < 0.001
2 (11.7%) 0 0.041
5 (27.7%) 5 (18.5%) 0.489
2 (11.1%) 2 (7.4%) ns
2 (11.1%) 2 (7.4%) ns
1 (5.5%) 4 (14.8%) 0.634
18 (100.0%) 24 (88.8%) 0.264
105  34 163  82 0.002
18 (100.0%) 23 (85.1%) 0.138
8.2  1.0 8.9  1.0 0.157
128  36 173  76 0.242
1.4  0.9 2.0  1.2 0.128
4 (22.2%) 2 (7.4%) 0.199
7 (38.8%) 8 (29.6%) 0.519
2 (11.1%) 7 (25.9%) 0.279
5 (27.7%) 7 (25.9%) ns
0 (0.0) 3 (11.1%) 0.264
0.53  0.19 0.45  0.21 0.229
0.91  0.17 0.87  0.19 0.459
0 5 (18.5%) 0.073
105  34 163  82 0.002
ntic Inter-Society Consensus.
lar treatment for TASC C and D aorto-iliac lesions, Asian Journal of
Figure 1 Primary patency curve for TASC C and D lesions.
TASC Z Trans-Atlantic Inter-Society Consensus.
Endovascular treatment for aorto-iliac lesions 5
+ MODELTASC D patients who failed technically was treated with
bifemoral bypass, two required medication only, and the
remaining two could not receive additional treatment due
to complications.3.4. Patency
The corresponding 2-year primary patency rates were 94.9%
for TASC C lesions and 88.4% for TASC D lesions (Figure 1);
however, there was no statistically significant difference
between the groups considering the primary patency. TASC
D lesions were reanalyzed to assess whether a stent hadTable 3 Comparison by approach.
Total
(nZ45 limbs)
Ipsilateral
(nZ6 limbs)
Counterlateral
(nZ15 limbs)
TASC C 18 (40.0%) 4 (66.6%) 7 (46.6%)
TASC D 27 (60.0%) 2 (33.3%) 8 (53.3%)
Right 25 (55.5%) 5 (83.3%) 8 (53.3%)
Left 20 (44.4%) 1 (16.6%) 7 (46.6%)
Occlusion 34 (75.5%) 4 (66.6%) 14 (93.3%)
Stump 34 (75.5%) 5 (83.3%) 11 (73.3%)
Aneurysm 1 (2.2%) 1 0
Calcification Score 2.1  0.5 1.8  0.4 2.1  0.5
Infrainguial lesion
A 10 (22.2%) 3 (50.0%) 3 (20.0%)
B 4 (8.8%) 0 2 (13.3%)
C 4 (8.8%) 0 2 (13.3%)
D 5 (11.1%) 0 1 (6.6%)
Technical success 42 (93.3%) 5 (83.3%) 15 (100.0%)
Complication rates 5 (11.1%) 0 1 (6.6%)
Procedure time 140  72 101  30 139  72
TASC Z Trans-Atlantic Inter-Society Consensus.
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3.5. Access site
The calcification score was higher in the patients treated
via the simultaneous brachial and femoral approach
(3  0.0; p < 0.001), and the simultaneous brachial and
femoral approach took the longest procedure time
(226  157 min; Table 3). Of the three simultaneous
brachial and femoral approach cases, only one was tech-
nically successful. In the two failed approaches, patients
expired due to iliac artery rupture, while the successfully
treated patient was transferred due to nosocomial pneu-
monia infection.
4. Discussion
This study demonstrated a 100% technical success rate and
a 94.4% primary patency at 2 years for TASC C lesions and an
88.8% technical success rate and 88.4% primary patency at
2 years for TASC D lesions. The complication rate was 0% for
TASC C lesions and 18.5% for TASC D lesions.
The TASC II guidelines in 2007 recommended surgical
bypass for TASC C and D aorto-iliac lesions. It stated
“Endovascular methods do not yield good enough results to
justify them as primary treatment” for TASC D lesions, and
“Open revascularization produces superior long-term re-
sults”, and “Endovascular methods should only be used
when there is a high risk associated with open repair” for
TASC C lesions.1
However, major changes were made between the TASC I
and TASC II classification, and more vascular surgeons are
attempting to treat TASC C and TASC D lesions with EVT.1,6
Moreover, technical and device improvements have
encouraged vascular surgeons to perform EVT for TASC C or
TASC D aorto-iliac lesions during the last 10 years.Only brachial
(nZ9 limbs)
Bifemoral
(nZ12 limbs)
Brachial & Femoral
(nZ3 limbs)
p
2 (22.2%) 5 (41.6%) 0 0.122
7 (77.7%) 7 (58.3%) 3 (100.0%) 0.122
6 (66.6%) 6 (50.0%) 0 0.098
3 (33.3%) 6 (50.0%) 3 (100.0%) 0.098
7 (77.7%) 6 (50.0%) 3 (100.0%) 0.383
8 (88.8%) 9 (75.0%) 1 (33.3%) 0.383
0 0 0 0.200
2.0  0.0 2.4  0.6 3  0.0 < 0.001
1 (11.1%) 3 (25.0%) 0 0.291
0 2 (16.6%) 0 0.829
1 (11.1%) 1 (8.3%) 0 ns
3 (33.3%) 0 1 (33.3) 0.554
9 (100.0%) 12 (100.0%) 1 (33.3) 0.220
1 (11.1%) 1 (8.3%) 2 (66.6) 0.067
169  44 118  63 226  157 < 0.001
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the results are high compared with those of TASC A and
TASC B lesions treated by EVT.7 Additionally, easy-to-repeat
procedures for re-stenosis constitute one reason for the
increasing trend for EVT.
In this study, only left brachial artery accesses were
performed in two limbs (22.2%) in TASC C lesions and in
seven limbs (77.7%) in TASC D lesions. Brachial access is
widely used in coronary interventions, but much less so in
noncoronary interventions. The main reasons for reluctant
use of brachial access are complications, such as hematoma
and arterial thromboembolism. These complications were
reported in 6% to 8% of cases.8,9 We performed brachial
access using the Seldinger technique in all patients, and
performed surgical closure after making a small incision.
There were no complications related to the use of brachial
access. The brachial approach offered a better pushability
in complex endovascular procedures, while the surgical
cut-down method can also be used safely.8
Both intraluminal endovascular interventions and sub-
intimal angioplasty can be appled to treat iliac chronic
total occlusionlesions. There was no difference in the pri-
mary patency (74% for the intraluminal approach and 76%
for subintimal angioplasty at the 3-year follow up).10,11.
We prefer primary stenting in TASC C and D aorto-iliac
lesions. AbuRahma et al.12 reported an overall early clinical
success rate of 93% for primary stenting and 46% for se-
lective stenting in TASC C and TASC D iliac lesions.12 A 2-
year primary patency rate of 94.4% in TASC C lesions and
88.4% in TASC D lesions in this study was comparable with
previous reports.
The technical success rate was higher in TASC C lesions
than in TASC D lesions, and complications were fewer in
TASC C lesions than in TASC D lesions. In a meta-analysis,
comparing TASC C lesions and TASC D lesions, no significant
difference was found between the two groups when
considering technical success.13 Other factors may have
played a role in the patients as important as the length of
the occlusion.14,15 Due to potential differences in patient
selection, a direct comparison of these results was not
possible.
Our study had some limitations. All data analyzed were
retrospective, although it was a prospective data collection
that originated from only two institutions. The techniques,
equipment, and experience of the surgeons also changed
during data collecting. This may have resulted in an over-
estimation of the technical success rate.
5. Conclusion
This study demonstrated that the outcomes of EVT for TASC
C and D aorto-iliac lesions were acceptable, with better
technical success in TASC C lesions than in TASC D lesions.Please cite this article in press as: Ahn S, et al., Outcomes of endovascu
Surgery (2016), http://dx.doi.org/10.1016/j.asjsur.2015.11.006Furthermore, the 2-year patency rate for both TASC C and
TASC D lesions was acceptable, and brachial access was
useful for complex anatomy, although with a high failure
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